Metastatic Malignant Melanoma
11
0
1
6
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
27.3%
3 terminated out of 11 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (11)
Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma
Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis
Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma
Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
Bevacizumab vs Dacarbazine in Metastatic Melanoma
A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
Inducing Systemic Immunity and Regressions in Metastatic Melanoma
A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma
Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study
Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
Temodar and Sutent as Therapy for Melanoma